Virtual high-throughput screening identifies mycophenolic acid as a novel RNA capping inhibitor

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Tremblay Létourneau, Maude ^a   Despins, Simon ^a   Bougie, Isabelle ^a   Bisaillon, Martin ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CAPPED RNA; ENZYME INHIBITOR; GUANOSINE PHOSPHATE; GUANOSINE TRIPHOSPHATE; MESSENGER RNA; MYCOPHENOLIC ACID; NUCLEOTIDYLTRANSFERASE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PYROPHOSPHATE; RNA GUANYLYLTRANSFERASE; RNA GUANYLYLTRANSFERASE INHIBITOR; RNA LIGASE; UNCLASSIFIED DRUG; 4 ALPHA GLUCANOTRANSFERASE; 4 ALPHA-GLUCANOTRANSFERASE; GLYCOGEN DEBRANCHING ENZYME; MESSENGER RIBONUCLEIC ACID GUANYLYLTRANSFERASE; RNA;

ARTICLE; ASSAY; CATALYSIS; CONTROLLED STUDY; DATA BASE; ENZYME INHIBITION; ENZYME SUBSTRATE; FUNGAL CELL; HIGH THROUGHPUT SCREENING; NONHUMAN; RNA CAPPING; RNA STRUCTURE; RNA SYNTHESIS; SACCHAROMYCES CEREVISIAE; SCREENING; STRUCTURAL HOMOLOGY; VIRTUAL REALITY; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; HUMAN; METABOLISM; PROTEIN SECONDARY STRUCTURE;

EUKARYOTA;

5'-GUANYLIC ACID; DNA LIGASES; ENZYME ACTIVATION; ENZYME INHIBITORS; GLYCOGEN DEBRANCHING ENZYME SYSTEM; HUMANS; MYCOPHENOLIC ACID; NUCLEOTIDYLTRANSFERASES; PROTEIN STRUCTURE, SECONDARY; RNA; RNA CAPS; SACCHAROMYCES CEREVISIAE;

EID: 84857462837     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024806     Document Type: Article

References (67)

1. Furuichi Y, Shatkin AJ, (2000) Viral and cellular mRNA capping: past and prospects. Adv Virus Res 55: 135-184.
2. Shuman S, (2001) Structure, mechanism, and evolution of the mRNA capping apparatus. Prog Nucleic Acid Res Mol Biol 66: 1-40.
3. Bisaillon M, Lemay G, (1997) Viral and cellular enzymes involved in synthesis of mRNA cap structure. Virology 236: 1-7.
4. Ghosh A, Lima CD, (2010) Enzymology of RNA cap synthesis. WIREs RNA 1: 152-172.
5. Issur M, Geiss BJ, Bougie I, Picard-Jean F, Despins S, et al. (2009) The flavivirus NS5 protein is a true RNA guanylyltransferase that catalyzes a two-step reaction to form the RNA cap structure. RNA 15: 2340-2350.
6. Bisaillon M, Lemay G, (1997) Characterization of the reovirus lambda1 protein RNA 5′-triphosphatase activity. J Biol Chem 272: 29954-29957.
7. Bouvet M, Debarnot C, Imbert I, Selisko B, Snijder EJ, et al. (2010) In vitro reconstitution of SARS-coronavirus mRNA cap methylation. PLoS Pathog 6: e1000863.
8. Myette JR, Niles EG, (1996) Characterization of the vaccinia virus RNA 5′-triphosphatase and nucleotide triphosphate phosphohydrolase activities. Demonstrate that both activities are carried out at the same active site. J Biol Chem 271: 11945-11952.
9. Shuman S, Hurwitz J, (1981) Mechanism of mRNA capping by vaccinia virus guanylyltransferase: characterization of an enzyme-guanylate intermediate. Proc Natl Acad Sci U S A 78: 187-191.
10. Ho CK, Van Etten JL, Shuman S, (1996) Expression and characterization of an RNA capping enzyme encoded by Chlorella virus PBCV-1. J Virol 70: 6658-6664.
11. Pugh CS, Borchardt RT, Stone HO, (1978) Sinefungin, a potent inhibitor of virion mRNA(guanine-7-)-methyltransferase, mRNA(nucleoside-2′-)-methyltransferase, and viral multiplication. J Biol Chem 253: 4075-4077.
12. Pugh CS, Borchardt RT, (1982) Effects of S-adenosylhomocysteine analogues on vaccinia viral messenger ribonucleic acid synthesis and methylation. Biochemistry 21: 1535-1541.
13. Zheng S, Hausmann S, Liu Q, Ghosh A, Schwer B, et al. (2006) Mutational analysis of Encephalitozoon cuniculi mRNA cap (guanine-N7) methyltransferase, structure of the enzyme bound to sinefungin, and evidence that cap methyltransferase is the target of sinefungin's antifungal activity. J Biol Chem 281: 35904-35913.
14. Paolantonacci P, Lawrence F, Robert-Gero M, (1985) Differential effect of sinefungin and its analogs on the multiplication of three Leishmania species. Antimicrob Agents Chemother 28: 528-531.
15. Benghiat E, Crooks PA, Goodwin R, Rottman F, (1986) Inhibition of vaccinia RNA guanine 7-methyltransferase by compounds designed as multisubstrate adducts. J Pharm Sci 75: 142-145.
16. Luzhkov VB, Selisko B, Nordqvist A, Peyrane F, Decroly E, et al. (2007) Virtual screening and bioassay study of novel inhibitors for dengue virus mRNA cap (nucleoside-2′O)-methyltransferase. Bioorg Med Chem 15: 7795-7802.
17. Podvinec M, Lim SP, Schmidt T, Scarsi M, Wen D, et al. (2010) Novel inhibitors of dengue virus methyltransferase: discovery by in vitro-driven virtual screening on a desktop computer grid. J Med Chem 53: 1483-1495.
18. Lima CD, Wang LK, Shuman S, (1999) Structure and mechanism of yeast RNA triphosphatase: an essential component of the mRNA capping apparatus. Cell 99: 533-543.
19. Gu M, Lima CD, (2005) Processing the message: structural insights into capping and decapping mRNA. Curr Opin Struct Biol 15: 99-106.
20. Issur M, Despins S, Bougie I, Bisaillon M, (2009) Nucleotide analogs and molecular modeling studies reveal key interactions involved in substrate recognition by the yeast RNA triphosphatase. Nucleic Acids Res 37: 3714-3722.
21. Shuman S, Liu Y, Schwer B, (1994) Covalent catalysis in nucleotidyl transfer reactions: essential motifs in Saccharomyces cerevisiae RNA capping enzyme are conserved in Schizosaccharomyces pombe and viral capping enzymes and among polynucleotide ligases. Proc Natl Acad Sci U S A 91: 12046-12050.
22. Doherty AJ, Hakansson K, Ho CK, Shuman S, Wigley DB, (1997) Crystallization of the RNA guanylyltransferase of Chlorella virus PBCV-1. Acta Crystallogr D Biol Crystallogr 53: 482-484.
23. Hakansson K, Doherty AJ, Shuman S, Wigley DB, (1997) X-ray crystallography reveals a large conformational change during guanyl transfer by mRNA capping enzymes. Cell 89: 545-553.
24. Souliere MF, Perreault JP, Bisaillon M, (2008) Kinetic and thermodynamic characterization of the RNA guanylyltransferase reaction. Biochemistry 47: 3863-3874.
25. Bougie I, Bisaillon M, (2004) The broad spectrum antiviral nucleoside ribavirin as a substrate for a viral RNA capping enzyme. J Biol Chem 279: 22124-22130.
26. Yan Y, Svitkin Y, Lee JM, Bisaillon M, Pelletier J, (2005) Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap. RNA 11: 1238-1244.
27. Ewing TJ, Makino S, Skillman AG, Kuntz ID, (2001) DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des 15: 411-428.
28. Fontaine F, Bolton E, Borodina Y, Bryant SH, (2007) Fast 3D shape screening of large chemical databases through alignment-recycling. Chemistry Central Journal 1: 1-14.
29. Wang R, Lai L, Wang S, (2002) Further development and validation of empirical scoring functions for structure-based binding affinity prediction. J Comput Aided Mol Des 16: 11-26.
30. Bougie I, Parent A, Bisaillon M, (2004) Thermodynamics of ligand binding by the yeast mRNA-capping enzyme reveals different modes of binding. Biochem J 384: 411-420.
31. Wen Y, Yue Z, Shatkin AJ, (1998) Mammalian capping enzyme binds RNA and uses protein tyrosine phosphatase mechanism. Proc Natl Acad Sci U S A 95: 12226-12231.
32. Sriskanda V, Shuman S, (1998) Mutational analysis of Chlorella virus DNA ligase: catalytic roles of domain I and motif VI. Nucleic Acids Res 26: 4618-4625.
33. Bisaillon M, Bougie I, (2003) Investigating the role of metal ions in the catalytic mechanism of the yeast RNA triphosphatase. J Biol Chem 278: 33963-33971.
34. Mayo SL, (1990) DREIDING: a generic force field for molecular simulations. J Phys Chem 94: 8897-8909.
35. Stewart JJ, (2007) Optimization of parameters for semiempirical methods V: modification of NDDO approximations and application to 70 elements. J Mol Model 13: 1173-1213.
36. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, et al. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19: 1639-1661.
37. Solis FJ, Wets RJB, (1981) Minimization by random search techniques. Math Oper Res 6.
38. Shuman S, (1995) Vaccinia virus DNA ligase: specificity, fidelity, and inhibition. Biochemistry 34: 16138-16147.
39. Sekiguchi J, Shuman S, (1997) Nick sensing by vaccinia virus DNA ligase requires a 5′ phosphate at the nick and occupancy of the adenylate binding site on the enzyme. J Virol 71: 9679-9684.
40. Schwer B, Mao X, Shuman S, (1998) Accelerated mRNA decay in conditional mutants of yeast mRNA capping enzyme. Nucleic Acids Res 26: 2050-2057.
41. Qiu Y, Fairbanks LD, Ruckermann K, Hawrlowicz CM, Richards DF, et al. (2000) Mycophenolic acid-induced GTP depletion also affects ATP and pyrimidine synthesis in mitogen-stimulated primary human T-lymphocytes. Transplantation 69: 890-897.
42. Ichikawa Y, Ihara H, Takahara S, Takada K, Shrestha GR, et al. (1984) The immunosuppressive mode of action of mizoribine. Transplantation 38: 262-267.
43. Allison AC, Hovi T, Watts RW, Webster AD, (1975) Immunological observations on patients with Lesch-Nyhan syndrome, and on the role of de-novo purine synthesis in lymphocyte transformation. Lancet 2: 1179-1183.
44. Sollinger HW, (1995) Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60: 225-232.
45. Papatheodoridis GV, O'Beirne J, Mistry P, Davidson B, Rolles K, et al. (1999) Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment: a preliminary report. Transplantation 68: 155-157.
46. Carter SB, Franklin TJ, Jones DF, Leonard BJ, Mills SD, et al. (1969) Mycophenolic acid: an anti-cancer compound with unusual properties. Nature 223: 848-850.
47. Quinn CM, Bugeja VC, Gallagher JA, Whittaker PA, (1990) The effect of mycophenolic acid on the cell cycle of Candida albicans. Mycopathologia 111: 165-168.
48. Scheidel LM, Stollar V, (1991) Mutations that confer resistance to mycophenolic acid and ribavirin on Sindbis virus map to the nonstructural protein nsP1. Virology 181: 490-499.
49. Alfieri C, Allison AC, Kieff E, (1994) Effect of mycophenolic acid on Epstein-Barr virus infection of human B lymphocytes. Antimicrob Agents Chemother 38: 126-129.
50. Takhampunya R, Ubol S, Houng HS, Cameron CE, Padmanabhan R, (2006) Inhibition of dengue virus replication by mycophenolic acid and ribavirin. J Gen Virol 87: 1947-1952.
51. Hermann LL, Coombs KM, (2004) Inhibition of reovirus by mycophenolic acid is associated with the M1 genome segment. J Virol 78: 6171-6179.
52. Sebastian L, Madhusudana SN, Ravi V, Desai A, (2011) Mycophenolic acid inhibits replication of Japanese encephalitis virus. Chemotherapy 57: 56-61.
53. Fabrega C, Shen V, Shuman S, Lima CD, (2003) Structure of an mRNA capping enzyme bound to the phosphorylated carboxy-terminal domain of RNA polymerase II. Mol Cell 11: 1549-1561.
54. Odell M, Sriskanda V, Shuman S, Nikolov DB, (2000) Crystal structure of eukaryotic DNA ligase-adenylate illuminates the mechanism of nick sensing and strand joining. Mol Cell 6: 1183-1193.
55. Lee JY, Chang C, Song HK, Moon J, Yang JK, et al. (2000) Crystal structure of NAD(+)-dependent DNA ligase: modular architecture and functional implications. EMBO J 19: 1119-1129.
56. Tomkinson AE, Levin DS, (1997) Mammalian DNA ligases. Bioessays 19: 893-901.
57. Ho CK, Van Etten JL, Shuman S, (1997) Characterization of an ATP-dependent DNA ligase encoded by Chlorella virus PBCV-1. J Virol 71: 1931-1937.
58. Sriskanda V, Shuman S, (1998) Chlorella virus DNA ligase: nick recognition and mutational analysis. Nucleic Acids Res 26: 525-531.
59. Davison AJ, Moss B, (1989) Structure of vaccinia virus early promoters. J Mol Biol 210: 749-769.
60. Issur M, Picard-Jean F, Bisaillon M, (2011) The RNA capping machinery as an anti-infective target. WIREs RNA 2: 184-192.
61. Liuzzi M, Mason SW, Cartier M, Lawetz C, McCollum RS, et al. (2005) Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase. J Virol 79: 13105-13115.
62. Elbarbry FA, Shoker AS, (2007) Therapeutic drug measurement of mycophenolic acid derivatives in transplant patients. Clin Biochem 40: 752-764.
63. Habib E, Leon F, Bauer JD, Hill RA, Carvalho P, et al. (2008) Mycophenolic Derivatives from Eupenicillium parvum. J Nat Prod 71: 1915-1918.
64. Scheidel LM, Durbin RK, Stollar V, (1987) Sindbis virus mutants resistant to mycophenolic acid and ribavirin. Virology 158: 1-7.
65. Jordan I, Briese T, Averett DR, Lipkin WI, (1999) Inhibition of Borna disease virus replication by ribavirin. J Virol 73: 7903-7906.
66. Planterose DN, (1969) Antiviral and cytotoxic effects of mycophenolic acid. J Gen Virol 4: 629-630.
67. Escobar-Henriques M, Balguerie A, Monribot C, Boucherie H, Daignan-Fornier B, (2001) Proteome analysis and morphological studies reveal multiple effects of the immunosuppressive drug mycophenolic acid specifically resulting from guanylic nucleotide depletion. J Biol Chem 276: 46237-46242.